Seer, Inc. (NASDAQ:SEER) Short Interest Update

Seer, Inc. (NASDAQ:SEER) was the recipient of a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 774,578 shares, a drop of 14.4% from the February 26th total of 904,811 shares. Approximately 1.5% of the company’s shares are short sold. Based on an average daily volume of 362,688 shares, the short-interest ratio is currently 2.1 days.

Seer Stock Performance

Shares of SEER opened at $1.70 on Thursday. The stock has a market capitalization of $95.91 million, a PE ratio of -1.33 and a beta of 1.59. Seer has a 1 year low of $1.62 and a 1 year high of $2.41. The company’s 50-day simple moving average is $1.84 and its 200-day simple moving average is $1.96.

Seer (NASDAQ:SEER) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. Seer had a negative net margin of 443.96% and a negative return on equity of 26.04%. The firm had revenue of $4.20 million during the quarter, compared to analysts’ expectations of $4.60 million. On average, sell-side analysts predict that Seer will post -1.42 earnings per share for the current year.

Institutional Trading of Seer

Several hedge funds have recently modified their holdings of SEER. Occudo Quantitative Strategies LP purchased a new position in Seer in the second quarter valued at $25,000. Quadrature Capital Ltd acquired a new position in Seer during the 2nd quarter worth $47,000. Marshall Wace LLP purchased a new stake in Seer during the 4th quarter worth about $85,000. Barclays PLC increased its holdings in Seer by 685.0% during the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock worth $111,000 after purchasing an additional 52,982 shares during the period. Finally, Corient Private Wealth LLC acquired a new stake in Seer in the 4th quarter valued at about $116,000. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on SEER shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Seer in a research report on Thursday, January 22nd. Wall Street Zen upgraded Seer to a “hold” rating in a research report on Saturday, December 13th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.